<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OTO</journal-id>
<journal-id journal-id-type="hwp">spoto</journal-id>
<journal-title>Otolaryngology–Head and Neck Surgery</journal-title>
<issn pub-type="ppub">0194-5998</issn>
<issn pub-type="epub">1097-6817</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0194599813491712</article-id>
<article-id pub-id-type="publisher-id">10.1177_0194599813491712</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Otology and Neurotology</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of Systemic Lipopolysaccharide-Induced Inflammation on Cytokine Levels in the Murine Cochlea</article-title>
<subtitle>A Pilot Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Quintanilla-Dieck</surname><given-names>Lourdes</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-0194599813491712">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Larrain</surname><given-names>Barbara</given-names></name>
<xref ref-type="aff" rid="aff2-0194599813491712">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Trune</surname><given-names>Dennis</given-names></name>
<degrees>PhD, MBA</degrees>
<xref ref-type="aff" rid="aff2-0194599813491712">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Steyger</surname><given-names>Peter S.</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-0194599813491712">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0194599813491712"><label>1</label>Department of Otolaryngology Head &amp; Neck Surgery, Oregon Health &amp; Science University, Portland, Oregon, USA</aff>
<aff id="aff2-0194599813491712"><label>2</label>Oregon Hearing Research Center, Oregon Health &amp; Science University, Portland, Oregon, USA</aff>
<author-notes>
<corresp id="corresp1-0194599813491712">Lourdes Quintanilla-Dieck, MD, Department of Otolaryngology Head &amp; Neck Surgery, Mail code PV01, Oregon Health &amp; Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239-3098, USA. Email: <email>quintani@ohsu.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>149</volume>
<issue>2</issue>
<fpage>301</fpage>
<lpage>303</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>12</month>
<year>2012</year>
</date>
<date date-type="rev-recd">
<day>30</day>
<month>4</month>
<year>2013</year>
</date>
<date date-type="accepted">
<day>7</day>
<month>5</month>
<year>2013</year>
</date>
</history>
<permissions>
<copyright-statement>© American Academy of Otolaryngology—Head and Neck Surgery Foundation 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">Official journal of the American Academy of Otolaryngology–Head and Neck Surgery Foundation</copyright-holder>
</permissions>
<abstract>
<p>The objective was to detect changes in cytokine expression within cochleae in a murine model of systemic inflammation, with or without aminoglycoside exposure. Four groups of mice received 1 of the following: saline only, systemic bacterial lipopolysaccharides (LPS) for 6 hours to induce endotoxemia and inflammatory responses, systemic gentamicin for 3 hours, or both treatments. After exsanguination, pooled cochleae (4/group) were processed for enzyme-linked immunosorbent assay (ELISA) for 16 cytokines. Gentamicin alone did not change cochlear cytokine levels, while LPS (±gentamicin) substantially elevated cochlear expression of several cytokines, particularly interleukin-1α, interleukin-6, monocyte chemotactic protein-1, macrophage inflammatory protein-1α, and RANTES. Since cytokines increase blood-brain barrier permeability, we hypothesize that cytokine-enhanced permeability of the blood-labyrinth barrier (BLB) could potentiate aminoglycoside-induced ototoxicity. This pilot study demonstrated the feasibility of detecting cytokine expression in murine cochleae using ELISA and facilitates future studies investigating BLB permeability in animal models of systemic inflammation.</p>
</abstract>
<kwd-group>
<kwd>aminoglycosides</kwd>
<kwd>cochlear cytokines</kwd>
<kwd>sepsis</kwd>
<kwd>systemic inflammation</kwd>
<kwd>ototoxicity</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0194599813491712" sec-type="intro">
<title>Introduction</title>
<p>Aminoglycosides like gentamicin are life-saving antibiotics, particularly for severe systemic bacterial sepsis. However, aminoglycoside therapy carries the risk of irreversible ototoxicity. Sepsis induces inflammatory responses that include the release of cytokines that can modulate the permeability of the blood-brain barrier.<sup><xref ref-type="bibr" rid="bibr1-0194599813491712">1</xref></sup> These inflammatory-mediated cytokines could also affect the permeability of the blood-labyrinth barrier (BLB) to nutrients and drugs.<sup><xref ref-type="bibr" rid="bibr2-0194599813491712">2</xref></sup> The goal of this pilot study was to determine the feasibility of detecting changes in cochlear levels of cytokines in a murine model of sepsis using bacterial lipopolysaccharide (LPS)-induced endotoxemia and subsequent inflammation with multiplex enzyme-linked immunosorbent assays (ELISA).</p>
</sec>
<sec id="section2-0194599813491712" sec-type="methods">
<title>Methods</title>
<p>Eight C57/B6 mice (28-42 days old) were divided into 4 groups, (a) vehicle controls receiving an intravenous (IV) tail injection of saline at 0 hours, then an intraperitoneal (IP) injection of saline at 3 hours; at the same time points, (b) received saline IV followed by gentamicin (300 mg/kg, a nonlethal dose<sup><xref ref-type="bibr" rid="bibr3-0194599813491712">3</xref></sup>) IP; (c) received LPS (1 mg/kg) IV, followed by saline IP; or (d) received both LPS and gentamicin. At 6 hours, mice were anesthetized and transcardially perfused with phosphate-buffered saline (PBS). Excised cochleae from each group were pooled, washed with PBS, immersed in a dithiothreitol and protease inhibitor cocktail, and homogenized using a BioMasher kit (Diagnocine, Hackensack, New Jersey). After centrifugation at 4°C, the 4 supernatant samples were sent to Quansys Biosciences for multiplex cytokine screen analysis (110451MS). Oregon Health &amp; Science University’s Institutional Animal Care and Use Committee approved this study.</p>
</sec>
<sec id="section3-0194599813491712" sec-type="results">
<title>Results</title>
<p>Substantial elevation in specific cochlear cytokines was observed in mice treated with LPS, with or without gentamicin treatment (<xref ref-type="fig" rid="fig1-0194599813491712"><bold>Figure 1</bold></xref>), particularly interleukin-1α (IL-1α), interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1α (MIP-1α), and RANTES (<xref ref-type="table" rid="table1-0194599813491712"><bold>Table 1</bold></xref>, <xref ref-type="fig" rid="fig2-0194599813491712"><bold>Figure 2</bold></xref>). Gentamicin did not induce substantive changes in cytokine levels. Due to the small sample size, no statistical analyses were performed.</p>
<fig id="fig1-0194599813491712" position="float">
<label>Figure 1.</label>
<caption>
<p>Cochlear cytokine protein levels for all 4 treatment groups in log scale for each cytokine tested.</p>
</caption>
<graphic xlink:href="10.1177_0194599813491712-fig1.tif"/>
</fig>
<table-wrap id="table1-0194599813491712" position="float">
<label>Table 1.</label>
<caption>
<p>Cytokine levels for each treatment group, for the same cytokines as <xref ref-type="fig" rid="fig2-0194599813491712">Figure 2</xref>.</p>
</caption>
<graphic alternate-form-of="table1-0194599813491712" xlink:href="10.1177_0194599813491712-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">IL-1α (pg/mL)</th>
<th align="center">IL-1β (pg/mL)</th>
<th align="center">IL-6 (pg/mL)</th>
<th align="center">MCP-1 (pg/mL)</th>
<th align="center">MIP-1α (pg/mL)</th>
<th align="center">RANTES (pg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td><bold>Controls</bold></td>
<td>6.73</td>
<td>19.64</td>
<td>3.35</td>
<td>2.00</td>
<td>5.58</td>
<td>12.20</td>
</tr>
<tr>
<td><bold>Gentamicin only</bold></td>
<td>7.11</td>
<td>34.01</td>
<td>3.55</td>
<td>6.57</td>
<td>9.19</td>
<td>17.64</td>
</tr>
<tr>
<td><bold>LPS only</bold></td>
<td>351.59</td>
<td>54.48</td>
<td>1826.78</td>
<td>450.27</td>
<td>303.58</td>
<td>623.52</td>
</tr>
<tr>
<td><bold>LPS and gentamicin</bold></td>
<td>278.37</td>
<td>37.49</td>
<td>1632.38</td>
<td>375.55</td>
<td>237.40</td>
<td>491.58</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0194599813491712">
<p>Abbreviations: IL-1α, interleukin-1α; IL-1β, interleukin-1β; IL-6, interleukin-6; MCP-1, monocyte chemotactic protein-1; MIP-1α, macrophage inflammatory protein-1α; LPS, lipopolysaccharide.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig2-0194599813491712" position="float">
<label>Figure 2.</label>
<caption>
<p>Bar graph for selected cytokines with substantial elevations in cochlear protein levels in log scale.</p>
</caption>
<graphic xlink:href="10.1177_0194599813491712-fig2.tif"/>
</fig>
</sec>
<sec id="section4-0194599813491712" sec-type="discussion">
<title>Discussion</title>
<p>These results show substantial changes in cochlear levels of selected cytokines in mice 6 hours after administration of LPS at 1 mg/kg, a dose that increased cochlear uptake of aminoglycosides without modulating drug plasma levels (unpublished data). This dose can also decrease expression of several renal transporters/channels, but does not induce arterial hypotension or renal ischemia.<sup><xref ref-type="bibr" rid="bibr4-0194599813491712">4</xref></sup> Gentamicin, at a nonlethal 300 mg/kg dose,<sup><xref ref-type="bibr" rid="bibr3-0194599813491712">3</xref></sup> did not affect cochlear cytokine levels within 3 hours.</p>
<p>Cytokines are intricately involved in the pathophysiology of any inflammatory response, and bacterial sepsis is no exception. Cytokines like IL-1β, IL-6, and TNF-α levels are all substantially increased in plasma at various time points during sepsis in humans and after LPS-induced inflammation as a model for sepsis in mice. In our study, 5 cytokines, IL-1α, IL-6, MCP-1, MIP-1α, and RANTES, were all substantially elevated in cochlear tissues 6 hours after systemic LPS injection. Although this study looked at <italic>one time point</italic>, 6 hours after LPS injection, it is likely that some or all cytokines will peak at other time points. A comparison between plasma and cochlear levels of cytokines over time is needed.</p>
<p>In this study, the most upregulated cytokines are primarily involved in cell-mediated immunity and cellular transmigration across endothelial barriers, particularly IL-1, IL-6, and MIP-1α. Cytokines that promote transepithelial migration may also alter the permeability of the BLB. Further research into the effect of these cytokines on the cochlear BLB will provide new insight into changes in BLB physiology, molecular trafficking, and the strial microenvironment during systemic inflammation and sepsis.</p>
<p>We propose that systemic inflammation, and sepsis, induce changes in cochlear cytokine levels that alter BLB permeability and the entry of ions, nutrients, and ototoxins into inner ear tissues. These pilot data demonstrate the feasibility in detecting substantial upregulation of specific cytokines in murine cochleae during LPS-induced endotoxemia and inflammation. The data suggest that the enhanced cochlear uptake of aminoglycosides during LPS-induced endotoxemia and inflammation might be modulated by inflammatory-mediated expression of cytokines that can regulate the permeability of the BBB,<sup><xref ref-type="bibr" rid="bibr1-0194599813491712">1</xref></sup> and likely also the BLB. This assumption needs to be tested in subsequent experiments.</p>
<p>There may be 2 cytokine-related phenomena occurring to regulate the permeability of the BLB: cytokine production within the cochlea and/or cytokine entry across the BLB from serum into the cochlea. Further studies, with larger sample size for statistical power, are needed to distinguish between the 2 phenomena. We can speculate on the potential effect of cytokines on the BLB. An inflammatory response could cause breakdown of tight junctions between strial endothelial cells, leading to paracellular influx of plasma into the stria vascularis, including drugs and proteins into the cochlea. Alternatively, cytokines may affect BLB physiology and transcellular trafficking across endothelial cells to account for the observed increase in cochlear uptake of aminoglycosides across the BLB. We hypothesize that inflammatory-mediated upregulation of cytokines, in serum or in the cochlea, increases cochlear BLB permeability to aminoglycosides and subsequent ototoxicity. Ongoing experiments will test this hypothesis.</p>
</sec>
<sec id="section5-0194599813491712">
<title>Author Contributions</title>
<p><bold>Lourdes Quintanilla-Dieck</bold>, conception and design, acquisition of data, analysis and interpretation of data, drafting and revising the article; <bold>Barbara Larrain</bold>, acquisition of data, analysis and interpretation of data; <bold>Dennis Trune</bold>, conception and design, analysis and interpretation of data, drafting and revising the article; <bold>Peter S. Steyger</bold>, conception and design, analysis and interpretation of data, drafting and revising the article.</p>
</sec>
<sec id="section6-0194599813491712">
<title>Disclosures</title>
<p><bold>Competing interests:</bold> None.</p>
<p><bold>Sponsorships:</bold> None.</p>
<p><bold>Funding source:</bold> Supported by NIH-NIDCD grants R01 DC004555 (PS), R01 DC005593 (DT), and Department of Otolaryngology at Oregon Health &amp; Science University.</p>
</sec>
</body>
<back>
<ack>
<p>Special thanks to Susan Griest, MPH, for discussions on the manuscript.</p>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.</p>
<p>This article was presented at the 2012 AAO-HNSF Annual Meeting &amp; OTO EXPO; September 9-12, 2012; Washington, DC.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0194599813491712">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Joan Abbott</surname><given-names>NJ</given-names></name>
<name><surname>Rönnbäck</surname><given-names>L</given-names></name>
<name><surname>Hansson</surname><given-names>E</given-names></name>
</person-group>. <article-title>Astrocyte–endothelial interactions at the blood-brain barrier</article-title>. <source>Nat Rev Neurosci</source>. <year>2006</year>;<volume>7</volume>:<fpage>41</fpage>-<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr2-0194599813491712">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Koo</surname><given-names>JW</given-names></name>
<name><surname>Wang</surname><given-names>Q</given-names></name>
<name><surname>Steyger</surname><given-names>P</given-names></name>
</person-group>. <article-title>Infection-mediated vasoactive peptides modulate cochlear uptake of fluorescent gentamicin</article-title>. <source>Audiol Neurootol</source>. <year>2011</year>;<volume>16</volume>:<fpage>347</fpage>-<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr3-0194599813491712">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>WJ</given-names></name>
<name><surname>Sha</surname><given-names>SH</given-names></name>
<name><surname>McLaren</surname><given-names>JD</given-names></name>
<name><surname>Kawamoto</surname><given-names>K</given-names></name>
<name><surname>Raphael</surname><given-names>Y</given-names></name>
<name><surname>Schacht</surname><given-names>J</given-names></name>
</person-group>. <article-title>Aminoglycoside ototoxicity in adult CBA, C57BL and BALB mice and the Sprague-Dawley rat</article-title>. <source>Hear Res</source>. <year>2001</year>;<volume>158</volume>:<fpage>165</fpage>-<lpage>178</lpage>.</citation>
</ref>
<ref id="bibr4-0194599813491712">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schmidt</surname><given-names>C</given-names></name>
<name><surname>Höcherl</surname><given-names>K</given-names></name>
<name><surname>Schweda</surname><given-names>F</given-names></name>
<name><surname>Bucher</surname><given-names>M</given-names></name>
</person-group>. <article-title>Proinflammatory cytokines cause down-regulation of renal chloride entry pathways during sepsis</article-title>. <source>Crit Care Med</source>. <year>2007</year>;<volume>35</volume>:<fpage>2110</fpage>-<lpage>2119</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>